real-time news and commentary for investors
Monday, Mar 25
Mast Therapeutics (MSTX +1.4%) gains today after the European Commission granted orphan-drug...
Mast Therapeutics (MSTX +1.4%) gains today after the European Commission granted orphan-drug designation to it's MST-188 drug candidate, a potential treatment for sickle cell disease. The decision gives MSTX 10 years of marketing exclusivity, and follows a similar positive opinion by the Committee for Orphan Medicinal Products. The company says it expects to now pursue strategic alliances "more aggressively."